FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225524074> ?p ?o ?g. }

• W4225524074 endingPage "406.e6" @default.
• W4225524074 startingPage "406.e1" @default.
• W4225524074 abstract "We previously reported the results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1101, a randomized comparison of hematopoietic cell transplantation (HCT) performed with double umbilical cord blood units (dUCB) or with haploidentical bone marrow (haplo-BMT) with post-transplantation cyclophosphamide (PTCy) in the nonmyeloablative setting. Those results showed similar progression-free survival in the 2 treatment groups but lower nonrelapse mortality and better overall survival in the haplo-BM arm. In this secondary analysis, we sought to investigate whether transplantation center's previous experience with haplo-BM and/or dUCB HCT had an impact on outcomes. All patients randomized in BMT CTN 1101 were included. Center experience was assigned based on the number of transplantations with each platform performed in the year before initiation of the study according to the Center for International Blood and Marrow Transplant Research. Centers were then classified as a dUCB center (>10 dUCB HCTs; n = 117 patients, 10 centers), a haplo-BM center (>10 haplo-BM HCTs and ≤10 dUCB HCTs; n = 110 patients, 2 centers), or other center (≤10 haplo and ≤10 dUCB HCTs; n = 140 patients, 21 centers). After adjusting for age, Karnofsky Performance Status, and Disease Risk Index, we found that haplo-BM centers had lower overall mortality with this donor type compared with dUCB centers (hazard ratio [HR], 2.56; 95% confidence interval [CI], 1.44 to 4.56). In contrast, there were no differences in overall mortality between haplo-BM and dUCB in centers that were experienced with dUCB HCT (HR, 1.02; 95% CI, .59 to 1.79) or had limited to no experience with either dUCB or haplo-BM HCT (HR, 1.36; 95% CI, .83 to 2.21). The higher risk of treatment failure and overall mortality in dUCB HCT in haplo BM-experienced centers was driven by a significantly higher risk of relapse (HR, 1.78; 95% CI, 1.07 to 2.97). With the exception of worse outcomes among dUCB HCT recipients in haplo-BM centers, transplantation center experience in the year before initiation of BMT CTN 1101 had a limited impact on the outcomes of this randomized clinical trial." @default.
• W4225524074 created "2022-05-05" @default.
• W4225524074 creator A5005850190 @default.
• W4225524074 creator A5009204664 @default.
• W4225524074 creator A5011838093 @default.
• W4225524074 creator A5013895038 @default.
• W4225524074 creator A5018922885 @default.
• W4225524074 creator A5024996698 @default.
• W4225524074 creator A5025687838 @default.
• W4225524074 creator A5029278364 @default.
• W4225524074 creator A5033267787 @default.
• W4225524074 creator A5040225749 @default.
• W4225524074 creator A5040328429 @default.
• W4225524074 creator A5041346359 @default.
• W4225524074 creator A5052064208 @default.
• W4225524074 creator A5052927157 @default.
• W4225524074 creator A5060944483 @default.
• W4225524074 creator A5062516204 @default.
• W4225524074 creator A5065373363 @default.
• W4225524074 creator A5072539716 @default.
• W4225524074 creator A5084606047 @default.
• W4225524074 creator A5085056360 @default.
• W4225524074 creator A5091433944 @default.
• W4225524074 date "2022-07-01" @default.
• W4225524074 modified "2023-10-14" @default.
• W4225524074 title "Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012" @default.
• W4225524074 cites W2067620376 @default.
• W4225524074 cites W2079023050 @default.
• W4225524074 cites W2087137028 @default.
• W4225524074 cites W2732703204 @default.
• W4225524074 cites W2741415205 @default.
• W4225524074 cites W2968557982 @default.
• W4225524074 cites W3044536206 @default.
• W4225524074 cites W3049396522 @default.
• W4225524074 cites W3082296557 @default.
• W4225524074 cites W3111771166 @default.
• W4225524074 cites W3129772109 @default.
• W4225524074 cites W3212530359 @default.
• W4225524074 doi "https://doi.org/10.1016/j.jtct.2022.03.024" @default.
• W4225524074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35390529" @default.
• W4225524074 hasPublicationYear "2022" @default.
• W4225524074 type Work @default.
• W4225524074 citedByCount "3" @default.
• W4225524074 countsByYear W42255240742022 @default.
• W4225524074 countsByYear W42255240742023 @default.
• W4225524074 crossrefType "journal-article" @default.
• W4225524074 hasAuthorship W4225524074A5005850190 @default.
• W4225524074 hasAuthorship W4225524074A5009204664 @default.
• W4225524074 hasAuthorship W4225524074A5011838093 @default.
• W4225524074 hasAuthorship W4225524074A5013895038 @default.
• W4225524074 hasAuthorship W4225524074A5018922885 @default.
• W4225524074 hasAuthorship W4225524074A5024996698 @default.
• W4225524074 hasAuthorship W4225524074A5025687838 @default.
• W4225524074 hasAuthorship W4225524074A5029278364 @default.
• W4225524074 hasAuthorship W4225524074A5033267787 @default.
• W4225524074 hasAuthorship W4225524074A5040225749 @default.
• W4225524074 hasAuthorship W4225524074A5040328429 @default.
• W4225524074 hasAuthorship W4225524074A5041346359 @default.
• W4225524074 hasAuthorship W4225524074A5052064208 @default.
• W4225524074 hasAuthorship W4225524074A5052927157 @default.
• W4225524074 hasAuthorship W4225524074A5060944483 @default.
• W4225524074 hasAuthorship W4225524074A5062516204 @default.
• W4225524074 hasAuthorship W4225524074A5065373363 @default.
• W4225524074 hasAuthorship W4225524074A5072539716 @default.
• W4225524074 hasAuthorship W4225524074A5084606047 @default.
• W4225524074 hasAuthorship W4225524074A5085056360 @default.
• W4225524074 hasAuthorship W4225524074A5091433944 @default.
• W4225524074 hasBestOaLocation W42255240741 @default.
• W4225524074 hasConcept C126322002 @default.
• W4225524074 hasConcept C141071460 @default.
• W4225524074 hasConcept C143998085 @default.
• W4225524074 hasConcept C203014093 @default.
• W4225524074 hasConcept C207103383 @default.
• W4225524074 hasConcept C2776694085 @default.
• W4225524074 hasConcept C2776755627 @default.
• W4225524074 hasConcept C2776955114 @default.
• W4225524074 hasConcept C2780007613 @default.
• W4225524074 hasConcept C2780073493 @default.
• W4225524074 hasConcept C2911091166 @default.
• W4225524074 hasConcept C44249647 @default.
• W4225524074 hasConcept C71924100 @default.
• W4225524074 hasConceptScore W4225524074C126322002 @default.
• W4225524074 hasConceptScore W4225524074C141071460 @default.
• W4225524074 hasConceptScore W4225524074C143998085 @default.
• W4225524074 hasConceptScore W4225524074C203014093 @default.
• W4225524074 hasConceptScore W4225524074C207103383 @default.
• W4225524074 hasConceptScore W4225524074C2776694085 @default.
• W4225524074 hasConceptScore W4225524074C2776755627 @default.
• W4225524074 hasConceptScore W4225524074C2776955114 @default.
• W4225524074 hasConceptScore W4225524074C2780007613 @default.
• W4225524074 hasConceptScore W4225524074C2780073493 @default.
• W4225524074 hasConceptScore W4225524074C2911091166 @default.
• W4225524074 hasConceptScore W4225524074C44249647 @default.
• W4225524074 hasConceptScore W4225524074C71924100 @default.
• W4225524074 hasFunder F4320306085 @default.
• W4225524074 hasFunder F4320332161 @default.
• W4225524074 hasFunder F4320332175 @default.
• W4225524074 hasFunder F4320337338 @default.

• next